# A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

> **NCT04976270** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3667
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04976270
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-20
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04976270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04976270, "A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04976270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*